SIGA: Shares of Siga Technologies (SIGA) were on the rebound Friday after having sunk to as low as below two dollars when rival PharmAthene (PIP) won a court ruling a couple of months ago that forces Siga to split profits of ST-246, a powerful antiviral for which Siga received a large government award earlier this year.

SIGA closed Friday at $2.43, up fifty nine cents and good for a thirty two percent gain, after Siga board member Fran Townsend granted an interview to CNN in which he quelled fears of impropriety surrounding the contract award. Some members of Congress have raised questions about the legitimacy of the contract, adding to the recent downward pressure to the SIGA stock, while other political conflicts of interest may also have contributed to the sagging share price.

More than triple the average volume sent SIGA shares soaring higher as Townsend's interview may have soothed enough investor concerns enough to spark a round of short covering, and the move could continue into the coming week as share went another ten percent higher during after-hours trading on Friday.

Siga, which also looked like a potential buyout candidate while shares were trading so low during all the uncertainty, could be in for an end-of-year rebound.

Definitely a story to watch during the coming week.

HGSI: Human Genome Sciences (HGSI) is another company whose stock had fallen while been heavily shorted and might now be on the rebound.

A report from the UK a couple of months ago had raised investor hopes that HGSI's partner for the lupus drug Benlysta, GlaxoSmithKline (GSK), was considering a complete buyout of Human Genome and the rumor sent HGSI shares to the north side of fifteen dollars.

Shares quickly came back down to earth, however, when nothing materialized from the buyout rumor and Benlysta continued to demonstrate evidence of a slower-than-expected commercial roll-out.

Having seen a fifty percent slice of its market cap in just a couple of months, HGSI looks to have bottomed at the seven dollar mark, and spent last week trading modestly higher before closing at $7.54.

With a potential bottom already found, count on another buyout rumor or two to pop up about Human Genome, which is a perennial buyout candidate.

Any news that would spark an increased pace of short covering could send shares back to the ten dollar mark in a hurry.

NBY: Volume has been on the rise for shares of NovaBay (NBY) as the company has attracted increasing interest for its proprietary treatments that may provide the medical community with an answer for antibiotic resistence.

Positive trial updates have recently hit the wires, with more results coming due in early 2012, and with a commecial launch of the chronic wound treatment NeutroPhase also set for the first half of next year, NBY will be a stock to watch for the coming month.

Nearly eight times the daily trading average switched hands on Friday, indicating that an active week may lie ahead.

AMZN: Amazon (AMZN) has gained some additional attention of late as a company who could potentially eat away at the digital media dominance of Netflix (NFLX) as that company tries to right a sinking ship, but some other news and moves are indicating that the best of days of Amazon have yet to be seen.

Recent ews from Bloomberg discusses huge onling sales numbers for holiday shopping, which not only is a good sign for the economy as a whole, but it also points to the potential profits that Amazon could rak in as the arguable leader in all things relating to online shopping.

Amazon has also moved into the app world.

The company's "price check" app, which allows a customer to scan an item in a retail store and instantly compare it to the Amazon price listing, is available for the iPhone and Android. An ongoing promotion allows consumers to receive discounted items from the Amazon shop for using the app, which creates the potential for additional sales, but has also led to backlash from those that see this as another attack on 'brick and mortar' retailers from the online shopping giant.

Keep an eye on Amazon, as this company's online dominance only looks to be growing - right at a time when it also looks like the economy might be picking up some steam.

GE: General Electric (GE) gained itself some investor interest last week when it was announced that the company would increase its quarterly dividend by 13%. The move by GE comes on the strength of GE Capital, which took a beating in the market meltdown of 2008, but is once again standing on firm footing.

Shares closed the day on Friday up just over three percent, and the move could continue higher towards the twenty dollar mark as investors and analysts regain confidence in the company and GE Capital fully recovers.

The trip back to twenty may not be immediate, but there's reason to believe again that there's a comfortable spot in the long term portfolio, or IRA, for General Electric.

CPST: Speaking of GE, shares of Capstone Turbine, a maker of low-emission microturbine units, were active last week as the result of the extension of a working relationship with GE. As per the extension, the current OEM agreement for GE's Heat Recovery Solutions segment Clean Cycle generators will be extended through January of 2016.

Additionally, GE has agreed to supply Capstone with parts through 2020.

CPST shares were sent to $1.13 when the news hit early in the week, although they quickly slipped back down to the dollar mark before rebounding by six percent on Friday.

Capstone was heavily shorted earlier in the year, but as the company's path towards profitability continues, this will be one to watch in 2012.

LPTN: Lpath Inc (OTCBB: LPTN) announced an offering last week to raise money to fund Lpathomab, one of the company's numerous pipeline products based on its bioactive lipid technology. Through its proprietary ImmuneY2, Lpath has developed the technology to generate therapeutic antibodies that can bind to and inhibit bioactive lipids and prevent the spreading and growth of various diseases and inflammatory/auto-immune disorders.

Being the only company to have taken this technology as far as it has, Lpath has already attracted a powerhouse partner in Pfizer (PFE) to help fund its leading programs, iSONEP and ASONEP in the treatment of Wet AMD and cancer, respectively, while last week's cash-raising event will help fund other preclinical development in the treatment of neuropathy, fibrosis and traumatic brain injury.

Shares did not react much to news of the offering, but volume has been picking up recently, keeping this one on the radar as a stock to watch.

CTSO: Another company that was out to raise funds last week was Cytosorbents (OTCBB: CTSO). The company announced that it has signed a purchase agreement for the sale, from time to time, of up to $8.5 million of its common stock to Lincoln Park Capital Fund.

The move will help fund the commercialization of CytoSorb in Europe, which was approved earlier this year for the treatment of indications where high cytokine counts are present, and will also be used to help fund any additional clinical trials that might be necessary for additional approvals.

Cytosorbents has seen its shares slip sharply from the post-approval highs, but 2012 could turn into a year of growth as CytoSorb gains market traction in Europe.

The company is also looking to license its HemoDefend technology to provide an additional source of funding.

Some investors may have been waiting to see the terms and conditions of any funding agreements before jumping on board, so with some of that now settled, CTSO could see more action during this coming trading week.

PBTH: Prolor Biotech (PBTH) is presenting this week at the Oppenheimer 22nd Annual Healthcare Conference in New York. With a similar presentation at the Lazard Capital Markets 8th Annual Healthcare Conference last month, word of Prolor and its novel Carboxyl Terminal Peptide (CTP) technology could be attracting increasing investor attention.

When CTP is attached to already-existing therapeutic proteins, it stabilizes the proteins in the bloodstream and, by slowing the process in which the protein is removed from the body, it creates an extended life span for the therapeutic treatment without adding toxicity or sacrificing the desired biological activity.

For instance, in its lead product candidate, hGH-CTP, Prolor's technology reduces the amount of weekly injections in victims of hormone deficiency from seven to one.

Keep an eye for increasing volume as the company presents at another major conference this week.

CELH: Volume for shares of Celsius Holdings (CELH) took a noticable turn for the higher last week, with trading days of over fifty thousand and thirty thousand shares traded mixed in with some lighter-volumed days. That's a significant boost, given that the daily average is just about eight thousand shares traded.

Celsius has made some heavy corporate movesover the past couple of months and could be gearing up for an attempt at a recovery while running a new market strategy for the Celsius calorie-burning beverage.

With volume on the upswing, keep an eye on CELH as a stock to watch for the coming week.

Happy trading.

Disclosure:  Long SIGA, HGSI, CELH, NBY, CPST, CTSO.

Add a Comment